Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services. It is a major producer of branded oncology medicines and hepatitis C drugs. The company specialises in producing complex medicines at affordable prices. In 2019, Natco launched its crop health sciences division..
The study focused on the rational design of recombinant human G-CSF (rhG-CSF) by structure-based single-site modification and process optimization. The research was conducted in two main stages. In the first stage, a new A7G point mutation was introduced to the 3D structure of rhG-CSF by means of computational design. The mutant model, following energy minimization, displayed satisfactory stereochemistry (Molprobity clashscore 2.32) and maintained the native fold, suggesting that the mutation is structurally compatible. The second phase involved optimization of a high-yield expression system with the use of recombinant vector pET3a in E. coli BL21(DE3). Optimization of culture conditions showed that 4XYT medium with 0.5 mM IPTG and a 17-hour induction time resulted in the highest level of expression of the mutant protein. Such conditions led to a very high biomass yield of 96 grams of cells. The novelty of the present research work lies in the incorporation of the structure-guided single residue modification and process optimization in one step, resulting in structurally validated A7G rhG-CSF and process optimization to 5 L scale in complex medium.
Objective: To provide a comprehensive review of parenteral product manufacturing with emphasis on aseptic processing, terminal sterilization, lyophilization technologies, and evolving regulatory requirements, while addressing current industry challenges and emerging trends. Methods: Critical analysis of FDA/EMA/WHO regulatory guidance (2020-2025), peer-reviewed literature, industry case studies, and recent technological advances in sterile manufacturing. Key Findings: The implementation of EU Annex 1 (2022) has introduced fundamental changes in contamination control strategies. Nitrosamine impurities have emerged as a critical quality concern across parenteral products. Advanced analytical technologies, including Process Analytical Technology (PAT) and real-time monitoring, are reshaping quality assurance approaches. Container-closure integrity testing has evolved from probabilistic to deterministic methods. The industry faces ongoing challenges in data integrity, environmental monitoring, and technology adoption while navigating complex regulatory expectations. Conclusions: Success in modern parenteral manufacturing requires integration of Quality by Design principles, risk-based approaches, and advanced technologies while maintaining robust sterility assurance. The balance between innovation and regulatory compliance remains critical for ensuring patient safety and product quality. Keywords: Parenteral products; aseptic processing; terminal sterilization; lyophilization; contamination control strategy; Quality by Design; regulatory compliance
TPS6108 Background: HNSCC is the seventh most common cancer worldwide. Patients with R/M disease have limited treatment options and a poor prognosis. The USFDA has approved two ICI agents to treat R/M-HNSCC: pembrolizumab given as monotherapy or with platinum-based chemotherapy for first-line treatment of R/M disease and nivolumab (or pembrolizumab) monotherapy for treatment of disease that progressed on or after platinum-containing chemotherapy. In each setting, the ICI improved overall survival (OS); however, the absolute magnitude of the OS benefit was modest and most patients experienced disease progression within one year. There are no agents with regulatory agency-approval that are used to treat R/M-HNSCC that progressed on or after an ICI. Drugs commonly used in this setting have limited activity and include cetuximab (an epidermal growth factor receptor [EGFR] inhibitor), paclitaxel, docetaxel, a platinum, or 5-fluorouracil. Hence, there is an important unmet medical need to develop more effective treatments for R/M-HNSCC that progressed on or after an ICI. NRC-2694-A is an orally administered EGFR tyrosine kinase inhibitor, discovered and developed by NATCO Pharma Ltd., India. Based on the responses from Phase-I and Phase-II trials of NRC-2694-A in India, NAT2694US study is designed to evaluate the safety and efficacy of Oral NRC-2694-A in combination with paclitaxel in patients with R/M-HNSCC, who progressed on or after ICI therapy. Methods: NAT2694US is a multi-center, single-arm, Phase 2 study (NCI ClinicalTrials.gov Identifier: NCT05283226) with an estimated enrolment of 46 patients. Eligible patients are >18 years of age with an ECOG performance status of 0-2 and histologically confirmed unresectable, measurable R/M-HNSCC (of the oral cavity, oropharynx, hypopharynx, and larynx), radiological disease progression on or after ICI therapy, and no prior taxane for R/M disease. Patients receive 300 mg of oral NRC-2694-A once daily and 175 mg/m² of paclitaxel IV infusion once every 21-day cycle for 6 cycles or more. Tumor response assessment with CT/MRI scans is performed every 6 weeks. The primary endpoint is objective response rate (ORR) using RECIST v1.1 performed by the investigator. The study uses a Simon’s 2-stage design with ORR H 0 : 30% and H 1 : 50% using a one-sided Type-1 error rate = 0.05). In Stage 1, fifteen patients are to be enrolled for tumor assessment. If objective response is observed in at least 6 of these 15 patients, then Stage 2 would be opened with the inclusion of 31 additional patients, leading to a total enrolment of 46 patients. The observation of objective response in at least 19 of 46 patients would reject the null hypothesis in favour of the alternative hypothesis. Enrolment to the NAT2694US trial is currently ongoing in USA. Clinical trial information: NCT05283226 .
The conventional Biginelli synthesis is more cumbersome and produces lower yields. Several improved methods are reported in the literature to replace the Biginelli catalyst. The design of biocompatible organic transformation is a major concern and a versatile greener procedure to construct Biginelli analogs is in great demand. Factorial design guided, energy-efficient, and versatile synthesis of 3,4-dihydropyrimidin-2-(1H)-ones (DHPM) was developed. One-factor-at-a time (OFAT) and factorial design (23) studies were utilized for screening the independent variables. The optimum levels of potential variables (benzyl-n-triethylammonium chloride (BTEAC) and glacial acetic acid) were determined through studies. The factorial design (32) analysis inferred the use of BTEAC (10.25 mol%) and glacial acetic acid (7.6 ml) as optimal for the 60 min condensation. Thirteen new 3,4dihydropyrimidine-2-(1H)-one (DHPM) analogs were synthesized using optimized reaction conditions. The quaternary ammonium ion of BTEAC stabilizes the polarization of carbonyl group in aryl aldehydes and enolizable ketone (alkyl acetoacetate) to facilitate the cyclocondensation, in order to produce DHPMs through N-acyliminium ion and Michael adducts formation. The biocompatible strategy, simple product isolation (non-chromatographic method), and good to excellent yields are attractive features of this new protocol. Hence, the newly developed methodology is superior to the literature methods.
